Department of Psychiatry
The Yale Department of Psychiatry is a world leader in patient care, research, and education. Our department prides itself on its diverse and talented faculty, including a cadre of compassionate clinicians, inter-disciplinary teams of talented investigators, and numerous committed and dedicated teachers, as well as a network of able alumni that remain vital to our missions.
As a department, we not only provide the highest quality of patient care, but also lead the nation in discoveries that are transforming our understanding and treatment of mental illness and addiction.
The department’s Psychology Section, with more than 200 full-time and voluntary faculty, is one of the largest and most accomplished groups of psychologists in an academic medical center.
Latest News
- December 08, 2023Source: American Journal on Addictions
The Influence of Childhood Trauma on the Effects of Delta-9-Tetrahydrocannabinol in Persons with Opioid Use Disorder
- December 07, 2023
VA/Yale Researchers Lead Study That Assesses Well-being of U.S. Veterans
- December 07, 2023Source: Scientific American
Hair Relaxers Will Be Safer without Formaldehyde, but It’s Just a Start
- December 07, 2023
VA/Yale Researchers Lead Multi-ancestry Study of Genetics of Problematic Alcohol Use
- December 05, 2023Source: Rochester Medicine
What the Streets Teach
- December 01, 2023
Garcia Vasallo Launches Training Program to Enhance Substance Use Disorder Care in Underserved Communities
- December 01, 2023
Education Collaboratory Team Member Spotlight: Dr. Almut Zieher
- November 30, 2023Source: Journal of Offender Rehabilitation
Readiness For Change: Assessing Employee Commitment to Peer Worker Integration in Drug Court Settings
Pioneering Interventional Psychiatric Services: Yale School of Medicine and Yale New Haven Health
00:02:46
Ketamine Clinical Trial
Parkinson disease not only affects a person's mobility, but also many other symptoms in a person with Parkinson disease life. Depression is a very common symptom caused by Parkinson disease, and adequate treatment is imperative for patients to feel their best. Through collaborations between Drs. Sophie E. Holmes and Gerard Sanacora of Psychiatry and the Movement Disorders group, researchers are conducting the first clinical trial of ketamine as an antidepressant in PD. Due to how it works in the brain – its ability to help form new synapses – they have strong reason to believe it will effectively treat depression, and possibly other symptoms, in PD. Using brain imaging before and after treatment will help to determine how it works in the brains of people with Parkinson’s for the first time. The trial is taking place at the Yale New Haven Psychiatric Hospital. In this video, hear more about the trial from Drs. Holmes and Sanacora and from Brenda, who talks about her experience participating in this groundbreaking research.
Department of Psychiatry Upcoming Events
Yale Only AZA Allsop - Angelique Bordey, PhD - Joy Hirsch, PhD - Dayu Lin - Lin Lin - Olivia Meisner - Anirvan Nandy, PhDYale Only Aaron Kuan
Everyone Daryn David, PhD
Department of Psychiatry Diversity, Equity and Inclusion Upcoming Events
Yale Only AZA Allsop - Angelique Bordey, PhD - Joy Hirsch, PhD - Dayu Lin - Lin Lin - Olivia Meisner - Anirvan Nandy, PhDYale Only Aaron Kuan
Everyone Daryn David, PhD